Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • craig2fletch craig2fletch Sep 3, 2013 9:25 AM Flag

    7:38 NBIX Neurocrine Biosci target raised to $19 at Oppenheimer ahead of more optimistic outlook for Ph.IIb KINECT Study (14.57 )

    7:38 NBIX Neurocrine Biosci target raised to $19 at Oppenheimer ahead of more optimistic outlook for Ph.IIb KINECT Study (14.57 )
    Oppenheimer raises their NBIX tgt to $19 from $16 NBIX's ph.IIb KINECT trial, which is assessing NBI-98854 in tardive dyskinesia (TD), is scheduled to report top-line results in early Sept. To better gauge physicians' expectations for '854 in TD, they interviewed two neurologist consultants specializing in hyperkinetic disorders. Despite data quality issues in ph.IIa, their consultants remain optimistic about '854's efficacy and anticipate positive results from the KINECT study. Given the lack of safe and effective therapies for TD, '854 would represent a significant improvement to the current standard-of-care, and they see potential for broad and rapid uptake of '854 in TD if approved.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBIX
49.62-0.15(-0.30%)Jul 26 4:00 PMEDT